China+1 for Medical Devices: Which Countries Make Sense?

China+1 for medical devices is becoming a practical sourcing and manufacturing strategy rather than a theoretical response to supply-chain risk. But moving production or procurement outside China is not as simple as choosing the country with the lowest labor cost. Medical devices require specialized suppliers, quality systems, skilled workers, component ecosystems and export infrastructure that can take years to develop.

For buyers, the question is which countries already have credible manufacturing depth for the products they source. For manufacturers, the same shift is creating opportunities to win business from companies actively adding second-source capacity. In 2026, four countries stand out for different reasons: Malaysia, India, Mexico and Costa Rica.

Why China+1 looks different for medical devices

China remains difficult to replace at scale. Its advantage extends beyond final assembly to plastics, electronics, metals, tooling, packaging, components and dense networks of specialized subcontractors. Moving final production elsewhere does not necessarily eliminate dependence on Chinese inputs.

Medical device buyers should therefore match countries to product categories rather than searching for one universal alternative. A location that makes sense for catheters and consumables may be a poor choice for diagnostic electronics or precision surgical components.

Malaysia: the strongest all-round Asian alternative

Malaysia already has one of the most mature medical device manufacturing ecosystems in Southeast Asia. The Malaysian Investment Development Authority lists manufacturing operations from companies including B. Braun, Dexcom, Boston Scientific, Smith+Nephew and Teleflex, alongside established supporting industries in electronics manufacturing services, plastics, rubber and engineering (MIDA, 2026).

The country is also moving beyond its historical strength in gloves and basic consumables. MIDA described Malaysia in July 2026 as transitioning from a build-to-print manufacturing base toward higher-value build-to-design medical technology production (MIDA, July 2026).

RM34.54 billion in medical device exports: Malaysia recorded RM34.54 billion in medical device exports in 2025 (MATRADE, 2026).

Malaysia is particularly compelling for buyers that want to diversify within Asia without moving far from established electronics and component supply chains. Medical consumables, catheters, surgical products, electronics and increasingly sophisticated devices fit the country's existing industrial base.

For manufacturers, Malaysia offers another advantage: it already exports medical devices to major developed markets. That makes it more than an emerging low-cost production location; it is an established export platform.

India: the scale play with growing MedTech ambitions

India offers something different: a huge domestic healthcare market combined with an explicit government push to expand medical device manufacturing. Its Production Linked Incentive scheme for medical devices has supported domestic production of higher-value products, while dedicated medical device parks are intended to strengthen manufacturing infrastructure (Department of Pharmaceuticals, 2026).

The government continues to support the sector in 2026 through the Scheme for Strengthening of Medical Device Industry, including initiatives around manufacturing capacity, skills and clinical studies. Indian policymakers are also increasingly positioning the country not only as a domestic manufacturing base but as a future MedTech exporter (Department of Pharmaceuticals, 2026).

India makes particular sense where scale, engineering talent and a large domestic supplier base matter. Its opportunity spans consumables and disposables through diagnostic equipment, implants and more sophisticated technologies.

But buyers should assess capabilities at manufacturer level rather than assuming India's overall industrial scale guarantees equivalent depth in every medical device category. The ecosystem is expanding quickly, but maturity varies significantly between product segments.

Mexico: the natural China+1 option for North America

For companies supplying the United States, Mexico has an advantage that Asian alternatives cannot reproduce: geography. Shorter transport routes, established cross-border manufacturing and major industrial clusters make Mexico particularly attractive when lead time and North American supply-chain integration matter.

Mexico's government highlighted Baja California and Chihuahua as major medical device and advanced-manufacturing centers at MD&M West in February 2026, with current investment efforts focused on supplier development, technology transfer and production relocation (Mexico Ministry of Economy, February 2026).

The country's medical device industry is not limited to basic assembly. Existing manufacturing includes increasingly sophisticated products, while border manufacturing clusters provide access to electronics, plastics, precision engineering and contract manufacturing capabilities.

Mexico therefore makes the strongest China+1 case for manufacturers whose primary customers are in the United States and for buyers that place a premium on shorter supply chains. Its value proposition is less about replacing China for every product and more about reducing distance between production and the world's largest medical device market.

Costa Rica: small country, heavyweight medical device cluster

Costa Rica is perhaps the most striking example of why medical device sourcing should not be judged by country size. Medical and precision equipment accounted for 44% of Costa Rica's goods exports in the first two months of 2026 (PROCOMER, March 2026).

By the first half of 2026, Costa Rican medical device exports had reached $5.382 billion, up 4% year over year. The country's ecosystem includes original equipment manufacturers, contract manufacturers and specialized suppliers in areas such as plastics, molds, sterilization, cleanrooms, metalworking and precision assembly (PROCOMER, August 2026).

$5.382 billion in first-half exports: Costa Rican medical device exports reached $5.382 billion in the first half of 2026 (PROCOMER, August 2026).

Costa Rica is particularly relevant for higher-value manufacturing destined for the Americas. More than 100 foreign-investment companies are connected to its medical device sector, and the country exports 164 product types to 88 markets (PROCOMER, 2026).

It will not compete with China or India on sheer industrial scale. Its strength is specialization: an unusually concentrated MedTech ecosystem, established multinational production and skilled manufacturing capabilities.

What about Vietnam and Thailand?

Both deserve attention, but neither should automatically be treated as a direct medical-device substitute for China. Vietnam has become a major alternative manufacturing location across several industries, yet its medical equipment market still depends heavily on imports. Around 90% of medical equipment used in Vietnam is imported, according to an updated U.S. International Trade Administration market assessment published in 2026 (U.S. International Trade Administration, 2026).

Thailand has a stronger established base in healthcare manufacturing and actively promotes medical device production, including high-risk and high-technology devices. It can be attractive for selected consumables, components and device categories, particularly for companies building an ASEAN manufacturing footprint (Thailand Board of Investment, 2026).

Both markets may become increasingly important, but buyers should distinguish general manufacturing strength from proven medical-device manufacturing depth.

Which China+1 country actually makes sense?

There is no single winner. Malaysia is arguably the most balanced Asian option because it combines an established medical device export industry with electronics, plastics and engineering capabilities. India offers scale and rapidly expanding manufacturing capacity. Mexico is difficult to beat for North American proximity, while Costa Rica offers a remarkably sophisticated specialist MedTech cluster.

The product should determine the geography. Buyers sourcing high-volume consumables may reach a different conclusion from those sourcing cardiovascular devices, diagnostic electronics, surgical instruments or precision components. Manufacturers evaluating a new production location face the same calculation in reverse.

China+1 should mean diversification, not relocation

The biggest mistake is treating China+1 as a search for the next China. No alternative market currently replicates China's combination of scale, infrastructure, supplier density and manufacturing breadth across every medical device category.

A stronger strategy keeps capable existing suppliers while identifying additional manufacturing ecosystems suited to specific products. Buyers should map critical components, sub-suppliers, production capacity and geographic dependencies before approving a second source. Manufacturers should understand where their own capabilities fill genuine gaps in increasingly diversified global supply chains.

Suplivia's network of 200,000+ medical products from 10,000 manufacturers across 80 countries can support this type of country-by-country comparison by helping sourcing professionals identify manufacturers beyond their established markets and evaluate alternative production geographies at product level.